The Week in Review: April 6 – April 13, 2018

Friday, April 13, 2018 News Recap: Canada: Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...

Ontario Expands Patient Access to Chronic Hepatitis C Therapies On Public Drug Plan

Gilead applauds Ontario's Ministry of Health for expanding access to curative hepatitis C therapies to all diagnosed patients, regardless of severity of illness Ontario's expanded access includes EPCLUSA®, a 12 week treatment for patients with chronic hepatitis C across all six genotypes Gilead's new product, VOSEVI™ is now available under the Ontario Drug Benefit Program The removal of the fibrosis level criterion for access furthers C...

The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Restrictions Lifted: All Swiss hepatitis C sufferers can access costly drugs like Harvoni

All patients suffering from hepatitis C can be treated with the drugs Harvoni and Epclusa from next month, after the Federal Office of Public Health lifted restrictions allowing the medicines to be reimbursed by mandatory health insurance. The two drugs will be available to all patients irrespective of the level and stage of infection, the office said in a statement on Tuesday. The brand-name drugs (sold as Harvoni or Epclusa) manufactured by American pha

France to provide universal access to hepatitis C treatment

France will provide access to hepatitis C treatment with direct-acting antivirals to everyone diagnosed with hepatitis C from September 2016, and will begin to provide treatment to everyone with stage 2 fibrosis immediately, health minister Marisol Touraine announced last week. Treatment will also be made available immediately for anyone with hepatitis C waiting for a liver transplant or experiencing a recurrence of hepatitis C infection after a liver tra

Christmas comes early for Australians living with hepatitis C

Thousands of Australians will rejoice at today’s announcement by Federal Health Minister Sussan Ley that a range of curative breakthrough hepatitis C medicines* will be added to the Pharmaceutical Benefits Scheme next year.Hepatitis Australia CEO Helen Tyrrell said that it was “simply terrific” that new ground-breaking medicines for hepatitis C would be subsidised on the PBS from 1 March 2016.“Last week, we were incredibly disheartened that the Mid-Year Ec